p53 mRNA - Hanmi Pharmaceutical
Alternative Names: Hanmi p53 mRNA; Lipid nanoparticle (LNP)-encapsulated mRNALatest Information Update: 31 Aug 2026
At a glance
- Originator Hanmi Pharmaceutical
- Class Antineoplastics; RNA
- Mechanism of Action Tumor suppressor protein p53 expression modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 17 Apr 2026 Pharmacodynamics data from preclinical studies in Cancer presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
- 25 Apr 2025 Preclinical trials in Cancer in South Korea (IV) before April 2025
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)